Search

Showing "11155" results for ""

Merck cuts price of efavirenz for developing countries again

HIV incidence rising in older gay men in Holland, most men recently infected undiagnosed

Women experience rapid fall in genital secretion of HIV after starting antiretovirals, but 50% still potentially infectious

Merck announces plans for licensing Atripla widely in developing world

Anti-herpes treatment reduces HIV levels; treatment or vaccine urged for HIV prevention

Health Canada issues warning on use of Baraclude alone in HIV/hepatitis B coinfected

Poor infection control, not poor adherence, responsible for vast majority of drug-resistant TB in Chinese study

CROI: Urgent action needed to avert `catastrophic` drug-resistant TB epidemic

CROI: Tenofovir microbicide stops rectal infection in monkeys better than PrEP

CROI: Growth hormone stimulant TH9507 safe and effective in HIV lipodystrophy

CROI: Alendronate effectively treats bone loss in men and women with HIV

CROI: Lower CD4 count on HIV treatment predicts higher risk of cancers, liver, kidney, cardiovascular disease

CROI: Efavirenz-based ART more effective than nevirapine-based ART as first-line therapy in Southern Africa

CROI: SMART analysis reveals slightly elevated risk of cardiovascular disease in people who interrupt therapy

CROI: MSF reports good responses on PI-based second-line ART regimens even though switch from failing regimens comes late

CROI: Women infected with HIV subtype D progress faster despite same viral load

CROI: Maraviroc shows potent effect in highly treatment-experienced

CROI: Microbicide failure poses more questions than answers

Receive the latest HIV research and conference news

Showing "11155" results for ""

Merck cuts price of efavirenz for developing countries again

HIV incidence rising in older gay men in Holland, most men recently infected undiagnosed

Women experience rapid fall in genital secretion of HIV after starting antiretovirals, but 50% still potentially infectious

Merck announces plans for licensing Atripla widely in developing world

Anti-herpes treatment reduces HIV levels; treatment or vaccine urged for HIV prevention

Health Canada issues warning on use of Baraclude alone in HIV/hepatitis B coinfected

Poor infection control, not poor adherence, responsible for vast majority of drug-resistant TB in Chinese study

CROI: Urgent action needed to avert `catastrophic` drug-resistant TB epidemic

CROI: Tenofovir microbicide stops rectal infection in monkeys better than PrEP

CROI: Growth hormone stimulant TH9507 safe and effective in HIV lipodystrophy

CROI: Alendronate effectively treats bone loss in men and women with HIV

CROI: Lower CD4 count on HIV treatment predicts higher risk of cancers, liver, kidney, cardiovascular disease

CROI: Efavirenz-based ART more effective than nevirapine-based ART as first-line therapy in Southern Africa

CROI: SMART analysis reveals slightly elevated risk of cardiovascular disease in people who interrupt therapy

CROI: MSF reports good responses on PI-based second-line ART regimens even though switch from failing regimens comes late

CROI: Women infected with HIV subtype D progress faster despite same viral load

CROI: Maraviroc shows potent effect in highly treatment-experienced

CROI: Microbicide failure poses more questions than answers

Receive the latest HIV research and conference news